Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Teresė Pipirienė-Želvienė"'
Autor:
Elona Juozaitytė, Eduardas Aleknavičius, Rasa Jančiauskienė, Alvydas Česas, Teresė Pipirienė-Želvienė, Sigita Liutkauskienė, Aurelija Krasauskienė, Lina Vencevičienė
Publikováno v:
Medicina, Vol 50, Iss 4, Pp 197-203 (2014)
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone heal
Externí odkaz:
https://doaj.org/article/58e3aab744ce4841b4432dff97f9ff53
Autor:
Lina Daukantienė, Konstantinas Povilas Valuckas, Eduardas Aleknavičius, Teresė Pipirienė-Želvienė
Publikováno v:
Lietuvos Chirurgija, Vol 12, Iss 3 (2013)
The purpose of this article is overview of currently available knowledge found in literature about the chemoradiation for locally advanced cervical cancer. Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of ca
Externí odkaz:
https://doaj.org/article/bc0a06a7537a49c29161f3f217c05d95
Autor:
Tadas Žvirblis, Ugnius Mickys, Eduardas Aleknavicius, Rokas Stulpinas, Teresė Pipirienė Želvienė, Edita Baltruškevičienė
Publikováno v:
Acta Medica Lituanica
Acta Medica Lituanica, Vol 23, Iss 1 (2016)
Acta Medica Lituanica, Vol 23, Iss 1 (2016)
Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevaciz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0f5b8abc1fb35826a0b9a980eca570
https://pubmed.ncbi.nlm.nih.gov/28356789
https://pubmed.ncbi.nlm.nih.gov/28356789
Autor:
Andrej Ostapenko, Teresė Pipirienė Želvienė, Valerijus Ostapenko, Raimundas Meskauskas, Giedrė Smailytė
Publikováno v:
Acta Medica Lituanica, Vol 20, Iss 4 (2014)
Background. Breast cancer is the most common female cancer worldwide. It is a heterogeneous disease with regard to biological behaviour, responses to treatment and prognosis. The term “triple negative breast cancer” (TNBC), namely, refers to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac633d995b0e617b9595b1731e602501
https://doi.org/10.6001/actamedica.v20i4.2816
https://doi.org/10.6001/actamedica.v20i4.2816
Autor:
Eduardas Aleknavicius, Lina Vencevičienė, Sigita Liutkauskienė, Elona Juozaitytė, Teresė Pipirienė-Želvienė, Alvydas Česas, Rasa Jančiauskienė, Aurelija Krasauskienė
Publikováno v:
Medicina, Vol 50, Iss 4, Pp 197-203 (2014)
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad00f3796201d7d4f135f69a1eb6358
Autor:
Laura Steponavičienė, Teresė Pipirienė Želvienė, Eduardas Aleknavicius, Nadežda Lachej-Mikerovienė
Publikováno v:
Acta medica Lituanica. 16:47-51
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b49bbe8b248cf85bc7df46835677be44
https://doi.org/10.2478/v10140-009-0007-7
https://doi.org/10.2478/v10140-009-0007-7
Autor:
Eduardas Aleknavicius, Teresė Pipirienė Želvienė, Nadežda Lachej, Laura Steponavičienė, Jūratė Liutkutė
Publikováno v:
Acta Medica Lituanica, Vol 22, Iss 1 (2015)
Įvadas. Vyrų krūties vėžys – reta onkologinė liga. Pasaulyje vyrai sudaro apie 1 % visų sergančiųjų krūties vėžiu. Lietuvos vėžio registro duomenimis, kasmet Lietuvoje nustatoma 10–14 naujų vyrų krūties vėžio atvejų. Medžiag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2037650489091901d08018156f10507a
https://www.journals.vu.lt/AML/article/view/21380
https://www.journals.vu.lt/AML/article/view/21380
Autor:
Elona, Juozaitytė, Eduardas, Aleknavičius, Rasa, Jančiauskienė, Alvydas, Cesas, Teresė, Pipirienė-Želvienė, Sigita, Liutkauskienė, Aurelija, Krasauskienė, Lina, Vencevičienė
Publikováno v:
Medicina (Kaunas, Lithuania). 50(4)
The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted treatment as well as highlight the importance of the multidisciplinary approach in the bone heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bcaeac5e2640bf3cd2010e0b20e84ca5
https://pubmed.ncbi.nlm.nih.gov/25458955
https://pubmed.ncbi.nlm.nih.gov/25458955
Autor:
Saulius Cicėnas, Romualdas Mickevičius, Teresė Pipirienė Želvienė, Vladislavas Vencevičius, Algirdas Jackevičius, Arnoldas Krasauskas
Publikováno v:
Lietuvos Chirurgija, Vol 5, Iss 3 (2007)
Algirdas Jackevicius, Saulius Cicėnas, Vladislavas Vencevicius, Arnoldas Krasauskas, Teresė Pipirienė - Želvienė, Romualdas Mickevicius Vilniaus universiteto Onkologijos institutas, Santariskių g. 1, LT-08660 Vilnius El pastas: algirdasj@is.lt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1033f81817b427d2461a9ddd1efd51bb
https://doi.org/10.15388/lietchirur.2007.3.2184
https://doi.org/10.15388/lietchirur.2007.3.2184
Autor:
Edita Baltruškevičienė, Ugnius Mickys, Tadas Žvirblis, Rokas Stulpinas, Teresė Pipirienė Želvienė, Eduardas Aleknavičius
Publikováno v:
Acta Medica Lituanica, Vol 23, Iss 1 (2016)
Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevaciz
Externí odkaz:
https://doaj.org/article/fa17ed972dde4cf8b35599e9f3dcaf34